JP2014516964A5 - - Google Patents

Download PDF

Info

Publication number
JP2014516964A5
JP2014516964A5 JP2014511445A JP2014511445A JP2014516964A5 JP 2014516964 A5 JP2014516964 A5 JP 2014516964A5 JP 2014511445 A JP2014511445 A JP 2014511445A JP 2014511445 A JP2014511445 A JP 2014511445A JP 2014516964 A5 JP2014516964 A5 JP 2014516964A5
Authority
JP
Japan
Prior art keywords
antibody
cdr
inhibitor
composition
irinotecan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2014511445A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014516964A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/037864 external-priority patent/WO2012158657A1/en
Publication of JP2014516964A publication Critical patent/JP2014516964A/ja
Publication of JP2014516964A5 publication Critical patent/JP2014516964A5/ja
Withdrawn legal-status Critical Current

Links

JP2014511445A 2011-05-18 2012-05-15 治療用抗igf1r合剤 Withdrawn JP2014516964A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161487452P 2011-05-18 2011-05-18
US61/487,452 2011-05-18
PCT/US2012/037864 WO2012158657A1 (en) 2011-05-18 2012-05-15 Therapeutic anti-igf1r combinations

Publications (2)

Publication Number Publication Date
JP2014516964A JP2014516964A (ja) 2014-07-17
JP2014516964A5 true JP2014516964A5 (https=) 2015-07-16

Family

ID=47177305

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014511445A Withdrawn JP2014516964A (ja) 2011-05-18 2012-05-15 治療用抗igf1r合剤

Country Status (6)

Country Link
US (1) US20140079665A1 (https=)
EP (1) EP2709661A4 (https=)
JP (1) JP2014516964A (https=)
AU (1) AU2012255920A1 (https=)
CA (1) CA2834566A1 (https=)
WO (1) WO2012158657A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150297613A1 (en) * 2011-12-13 2015-10-22 Servicio Andaluz De Salud Use of agents that alter the peritumoral environment for the treatment of cancer
ES2541870B1 (es) 2013-12-27 2016-05-12 Servicio Andaluz De Salud Uso de antagonistas no peptídicos de NK1 en una determinada dosis para el tratamiento del cáncer
KR102053507B1 (ko) * 2014-06-02 2019-12-06 내셔널 양밍 유니버시티 약물 내성 암을 치료하는 방법
ES2909576T3 (es) 2016-10-11 2022-05-09 Univ Duke Tratamiento con lasofoxifeno del cáncer de mama ER+
US20180221476A1 (en) * 2017-02-06 2018-08-09 Oncoquest Nc. Treatment of cancer with therapeutic monoclonal antibody specific for a tumor associated antigen and an immune adjuvant
US11497730B2 (en) 2018-04-10 2022-11-15 Duke University Lasofoxifene treatment of breast cancer
US20220267450A1 (en) 2020-10-14 2022-08-25 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease
EP4384219A4 (en) 2021-08-10 2025-06-18 Viridian Therapeutics, Inc. COMPOSITIONS, DOSAGES AND METHODS FOR THE TREATMENT OF THYROID EYE DISEASE
GB202116903D0 (en) 2021-11-18 2022-01-05 Sermonix Pharmaceuticals Inc Lasofoxifene treatment of aromatase-resistant er+ cancer
IL318499A (en) 2022-07-30 2025-03-01 Pinetree Therapeutics Inc Compounds for targeted lysosomal degradation and methods of using them

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100226884A1 (en) * 2009-01-20 2010-09-09 Immunomedics, Inc. Novel Class of Monospecific and Bispecific Humanized Antibodies that Target the Insulin-like Growth Factor Type I Receptor (IGF-1R)
WO2011057064A1 (en) * 2009-11-05 2011-05-12 Brian Long Igf1r inhibitor based treatment of prostate cancer
US20130287763A1 (en) * 2010-07-28 2013-10-31 Merck Sharp & Dohme Corp. Combination therapy for treating cancer comprising an igf-1r inhibitor and an akt inhibitor

Similar Documents

Publication Publication Date Title
JP2014516964A5 (https=)
JP2011515478A5 (https=)
US12351630B2 (en) PD1 and/or LAG3 binders
WO2019199621A4 (en) Bi-functional molecules to degrade circulating proteins
JP2011519868A5 (https=)
WO2008076278A4 (en) Methods of cancer treatment with igf1r inhibitors
JP2019503674A5 (https=)
JP7379345B2 (ja) 抗pd-1/lag3二重特異性抗体
AU2019301944B2 (en) 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of IKAROS Family Zinc Finger 2 (IKZF2)-dependent diseases
RU2018123481A (ru) Анти-lag3 антитела и антигенсвязывающие фрагменты
AU2016355569B2 (en) CTLA4 binders
RU2010120674A (ru) Полностью человеческие анти-vegf-антитела и способы их применения
IL319363A (en) Cervalon ligands and bifunctional compounds containing them
JP2022549169A5 (https=)
JP2005527222A5 (ja) 中和ヒト抗igfr抗体
JP2016519091A5 (https=)
JP2021526136A5 (https=)
KR20170065466A (ko) 인간vegf-a에 특이하게 강한 결합 친화도 및 인간vegf-b에 교차 반응성을 가진 항-인간vegf 항체
CA2896058A1 (en) Prolactin receptor binding proteins and uses thereof
TW201110980A (en) Combination therapy of an afucosylated CD20 antibody with bendamustine
CA3089075A1 (en) Anti-pd-1 antibodies
JP2014516964A (ja) 治療用抗igf1r合剤
JP2017538673A5 (https=)
RU2014153440A (ru) Антитела против cd26 и их применение
RU2019125975A (ru) Связывающие агенты